Home | Publications | Diagnostics place holder
place holder place holder

Diagnostics

Diagnostics and Therapeutics for Genetic Diseases


Publication Date   April 2006
Publisher   Business Communications Company
Product Type   Report
Pages   150
ISBN Number   not applicable
Product Code   BCC034
Ask a question about this product?

Price £2,410.00

approximately: $4,503 | €3,057

Summary


This important BCC Research study determines the current status of genetic disease therapies and assesses the growth potential of the industry in the United States over a five-year period from 2005 to 2010. For each single gene disease, the analysis examines the current diagnostic and therapeutic options and the projected market through 2010. It also identifies up-and-coming developments in the pharmaceutical, transplant, and transfusion industries.

Scope Of Study

This timely study:

  • Examines common genetic diseases that result from a single mutation, namely Cystic Fibrosis, Down Syndrome, Duchenne and Becker Muscular Distrophy, Fragile X Syndrome, Hemophilias, Polycystic Kidney Disease, Sickle Cell and related anemias, and Thalassemias
  • Outlines the genetic causes, common mutations, diagnostic methods and disease pathology for each of the most frequent monogenic diseases
  • Discusses current and emerging treatments, and analyzes the markets for each, with forecasts projected through 2010. Treatment markets include various types of pharmaceutical agents, transplants, and transfusions
  • Profiles major companies and their market shares
  • Evaluates significant patents
  • Presents an outlook on future directions and challenges.

Report Highlights

  • The U.S. market for therapeutics and diagnostics for genetic diseases reached $4.8 billion in 2005 and is expected to grow at an average annual rate of 8.7%, reaching $7.3 billion by 2010.
  • Transfusions and dialysis comprised 44% of the total market in 2005 and are projected to grow at an annual rate of 8.0%.
  • Pharmaceuticals for genetic disease treatment reached $2.7 billion in 2005. They are expected to grow at an average annual rate of 9.4% to reach a projected $2.7 billion by 2010.
  • The market for diagnostic testing reached $663.6 million in 2005. It is projected to grow at an annual rate of 9.3% to reach a projected $1036.7 million in 2010.
  • The market for transplants to treat genetic diseases was $280.6 million in 2005 and is expected to grow at an average annual rate of 8.2% to reach a projected $416.1 million in 2010.

Content


  • Introduction
    • Study Goal And Objectives
    • Scope And Format
    • Contributions Of The Study And Audience
    • Methodology And Information Sources
    • About The Author
    • Related BCC Reports
    • BCC Online Services
    • Disclaimer
  • Summary
    • Summary Table: U.S. Market For Therapeutics And Diagnostics For Genetic Diseases, By Segment Through 2010 ($ Millions)
    • Summary Figure: U.S. Market For Therapeutics And Diagnostics For Genetic Diseases, By Segment, 2000-2010 ($ Millions)
  • Overview
    • Introduction To Monogenic Diseases
      • Genetic Testing
      • Carrier Screening
      • Prenatal Diagnostic Testing
        • Ultrasound
        • Amniocentesis
        • Chorionic Villus Sampling (CVS)
        • Maternal Serum Alpha-Fetoprotein (MSAFP)
        • Triple Or Quadruple Screen
        • Advanced Maternal Age
        • Maternal Medical Problems
        • Genetic Counseling
      • Preimplantation Diagnosis
      • Newborn Screening
      • Presymptomatic Testing
      • Confirmative Diagnosis
    • Successes And Limitations Of Genetic Testing
    • Regulatory Policies
    • Insurance
  • Market By Disease Segment
    • Cystic Fibrosis
      • Introduction
      • Genetics
      • Symptoms
        • Mild To Moderate Cf Lung Disease
        • Advanced/Severe Cf Lung Disease
        • Pancreatic Insufficiency
        • Diabetes
        • Liver Damage
        • Fertility
        • Osteoporosis
      • Diagnosis
      • Treatment Overview
      • Diagnostics For Cystic Fibrosis
      • Pharmaceuticals In Treatment Of Cystic Fibrosis
        • Bronchodilators
        • Dnase
        • Pancreatic Enzyme Therapy
      • Corticosteroids
      • Antibiotics
        • The Market For Pharmaceuticals In The Treatment Of Cf
        • Bronchodilators
        • Pancreatic Enzyme Therapies
        • Corticosteroids
        • Antibiotics
      • Transplants In Treatment Of Cystic Fibrosis
        • Transplant Timing
        • Lung Function
        • Market For Transplants In The Treatment Of Cystic Fibrosis
      • Future Directions In Cf Treatment
        • Ion Channel Modulators
        • Curcumin
        • Living Donor Transplants
        • Gene Therapy
    • Duchenne And Becker Muscular Dystrophy
      • Introduction
      • Mutations
      • Symptoms
      • Diagnosis
      • Treatment
      • Diagnostics For Dmd/Bmd
        • Pharmaceuticals For The Treatment Of Muscular Dystropies
        • Physiotherapy
        • Mechanical Ventilatory Assistance/Volume Ventilators
      • Future Directions In Dmd/Bmd Treatment
      • Hemophilias
      • Hemophilia A
        • Symptoms
        • Genetics
        • Diagnosis
        • Therapy
      • Hemophilia B
        • Genetics
      • Hemophilia C
      • Von Willebrand Disease
      • Hemophilia Treatment
      • Diagnostics For Hemophilias
      • Pharmaceuticals In Treatment Of Hemophilias
        • Replacement Therapy
        • Other Pharmaceuticals
        • Desmopressin
        • Antifibrinolytic Drugs
        • Market For Pharmaceuticals In The Treatment Of Hemophilias
      • Transplants In Treatment Of Hemophilias
      • Future Directions
        • Improved Purification Processes
        • Gene Therapy
    • Hereditary Hemochromatosis
      • Introduction
      • Genetics
      • Symptoms
      • Diagnosis
      • Treatment
      • Diagnostics For Hereditary Hemachromatosis
      • Transfusions/ Phlebotomy In The Treatment Of Hereditary Hemachromatosis
    • Polycystic Kidney Disease
      • Introduction
      • Genetics
      • Diagnosis
      • Autosomal Dominant Pkd
        • Symptoms
        • Diagnosis
        • Treatment
        • Pain Relief
        • Urinary Tract Infections
        • High Blood Pressure
        • End-Stage Renal Disease (ESRD)
      • Autosomal Recessive Pkd
        • Genetics
        • Symptoms
        • Diagnosis
        • Treatment Overview
        • The U.S. Market For Polycystic Kidney Disease Therapeutics
      • Diagnostics For Polycystic Kidney Disease
      • Pharmaceuticals In Treatment Of Polycystic Kidney Disease
        • Vitamin D Analogues
        • Erythropoietin (EPO)
        • Iv Iron Therapy
      • Dialysis In Treatment Of Polycystic Kidney Disease
      • Transplants In Treatment Of Polycystic Kidney Disease
    • Sickle Cell And Related Anemias
      • Introduction
      • Genetics
      • Symptoms
        • Vasoocclusive Crises
        • Aplastic Crisis
        • Splenic Sequestration Crisis.
      • Diagnosis
        • Newborn Screening
      • Treatment Overview
        • Febrile Illness
        • Painful (Vaso-Occlusive) Crises
        • Acute Chest Crisis
        • Hydroxyurea
        • Blood Transfusions
      • Diagnostics For Sickle Cell Anemia
      • Pharmaceuticals In Treatment Of Sickle Cell And Related Anemias
        • Hydroxyurea
        • Emerging Pharamceuticals
        • Erythropoietin (EPO)
        • Clotrimazole
        • Fluocor
      • Transfusions In Treatment Of Sickle Cell And Related Anemias
      • Future Treatments
    • Thalassemias
      • Introduction
      • Alpha Thalassemia
        • Genetics
        • Symptoms
      • Beta (B) Thalassemias
        • Genetics
        • Symptoms
      • Delta (D) Thalassemia
      • Thalassemia In Combination With Other Hemoglobinopathies
      • Diagnosis
      • Treatment Overview
      • Diagnostics For Thalassemia
      • Transfusions In Treatment Of Thalassemia
      • Future Treatments
  • Emerging Therapeutic Targets
    • Enzymatic Deficiencies
      • Alpha-1-Antitrypsin Deficiency
        • Symptoms
        • Genetics
        • Treatment
      • Gaucher Disease
        • Symptoms
        • Diagnosis
        • Genetics
        • Treatment
      • Phenylketonuria
        • Diagnosis
        • Treatment
    • Motor-Nervous System Diseases
      • Amyotrophic Lateral Sclerosis
        • Symptoms
        • Diagnosis
        • Genetics
        • Treatment
      • Future Directions
      • Fragile X Syndrome
        • Genetics
        • Diagnosis
        • Treatment
      • Canavan Disease
        • Symptoms
        • Genetics
        • Treatment
      • Neurofibromatosis Type 1
        • Genetics
        • Symptoms
        • Diagnosis
        • Treatment
    • Immune System Disorders
      • Ataxia Telangiectasia
        • Genetics
        • Symptoms
        • Treatment
        • Diagnosis
    • Metabolic Disorders
      • Maple Syrup Urine Disease
        • Symptoms
        • Genetics
        • Treatment
      • Niemann-Pick Disease
        • Genetics
        • Treatment
      • Tay-Sachs Disease
        • Symptoms
        • Genetics
        • Treatment And Future Directions
      • Mucopolysaccharide Disease (Hurler's Disease, Sanfillipo Syndrome, Hunter's Syndrome)
        • Mps-I H, Hurler Syndrome
        • Diagnosis
        • Treatment
        • Mps-Ii, Hunter Syndrome
        • Genetics
        • Symptoms
        • Diagnosis
        • Treatment
        • Mps-Iii, Sanfillipo Syndrome
        • Diagnosis
        • Treatment
        • Future Therapies
  • Market By Product Type
    • Diagnostics For Genetic Disease
    • Pharmaceutical Treatments Of Genetic Disease
    • Transplantation Treatment Of Genetic Disease
    • Transfusion Treatment Of Genetic Disease
  • Patent Evaluation
    • Recent Patents Of Significance
      • Method For Upregulation Of Cf Transmembrane Membrane Conductance Regulators
      • Enhancers Of Cftr Chloride Channel Function
      • Potential Nutraceutical Treatment For Pkd
      • Screening Method For Compounds To Treat Pkd
      • Glycosylated, Low Antigenicity Low Immunogenicity Factor Viii
      • Antiviral Agent For Prevention Of Cell Sickling
  • Outlook
    • Future Directions
      • Identification Of Modifier Genes And Mutations
      • Non-Invasive Prenatal Testing
      • Gene Therapy
      • Stem Cell Therapy
    • Challenges And Ethical Considerations
      • Insurance Coverage
      • Over-The-Counter Options
      • Prenatal Testing
    • Company Profiles
      • Amgen
      • Athena Diagnostics, Inc.
      • Chiron, Inc
      • Genaera Corp
      • Genentech Inc.
      • Genzyme Corp.
      • Laboratory Corporation Of America (LABCORP)
      • Maxygen
      • Millenium Pharmaceuticals
      • Myriad Genetics
      • Orchid Biosciences
      • Pfizer Inc.
      • Quest Diagnostics
      • Roche (F. Hoffmann-La Roche Ltd)
      • Sanofi-Aventis
      • Vertex Pharmaceuticals, Inc
      • Wyeth-Ayerst, Inc.
  • List Of Figures
    • Summary Table: U.S. Market For Therapeutics And Diagnostics For Genetic Diseases, By Segment Through 2010 ($ Millions)
    • Table 1 Maternal Age And Risk Of Chromosomal Abnormalities
    • Table 2 Newborn Screening Recommended By The American College Of Medical Genetics
    • Table 3 States With Mandated Newborn Screening For All 29 Of The Recommended Acmg Disorders, December 2005
    • Table 4 States With Mandated Newborn Screening For At Least 20 Of The Recommended Acmg Disorders, December 2005
    • Table 5 Common Dna-Based Gene Tests
    • Table 6 Incidence Of Common Mutations In Cystic Fibrosis In The United States
    • Table 7 U.S. Market For Cystic Fibrosis Therapeutics By Segment, Through 2010 ($ Millions)
    • Table 8 U.S. Market For Cystic Fibrosis Diagnostics Testing By Segment, Through 2010 ($ Millions)
    • Table 9 Health-Related Economic End Points Of Pulmozyme Reported During A 24-Week Study
    • Table 10 Major Manufacturers Of Pancreatic Enzyme Therapies
    • Table 11 U.S. Market For Pharmaceuticals In Treatment Of Cystic Fibrosis By Product Type, Through 2010 ($ Millions)
    • Table 12 U.S. Market For Transplants In Treatment Of Cystic Fibrosis, By Product Type, Through 2010 ($ Millions)
    • Table 13 U.S. Market For Muscular Dystrophy Therapeutics, By Segment, Through 2010 ($ Millions)
    • Table 14 U.S. Market For Dmd/Bmd Diagnostics By Segment, Through 2010 ($ Millions)
    • Table 15 U.S. Market For Pharmaceuticals In Treatment Of Dmd/Bmd By Product Type, Through 2010 ($ Millions)
    • Table 16 U.S. Market For Hemophilia Therapeutics By Segment, Through 2010 ($ Millions)
    • Table 17 U.S. Market For Hemophilia Diagnostics By Segment, Through 2010 ($ Millions)
    • Table 18 Major Clotting Factor Replacement Therapies And Manufacturers In The U.S.
    • Table 19 U.S. Market For Pharmaceuticals In The Treatment Of Hemophilias By Product Type, Through 2010 ($ Millions)
    • Table 20 Gene Therapy Trials For Hemophilia
    • Table 21 U.S. Market For Hereditary Hemachromatosis Therapeutics, By Segment, Through 2010 ($ Millions)
    • Table 22 U.S. Market For Hereditary Hemachromatosis Diagnostics By Segment, Through 2010 ($ Millions)
    • Table 23 U.S. Market For Transfusions In The Treatment Of Hereditary Hemachromatosis By Product Type, Through 2010 ($ Millions)
    • Table 24 U.S. Market For Polycystic Kidney Disease Therapeutics By Segment, Through 2010 ($ Millions)
    • Table 25 U.S. Market For Polycystic Kidney Disease Diagnostics By Segment, Through 2010 ($ Millions)
    • Table 26 U.S. Market For Pharmaceuticals In The Treatment Of Polycystic Kidney Disease By Product Type, Through 2010 ($ Millions)
    • Table 27 U.S. Market For Dialysis In Treatment Of Polycystic Kidney Disease By Product Type, Through 2010 ($ Millions)
    • Table 28 U.S. Market For Transplants In Treatment Of Polycystic Kidney Disease, By Product Type, Through 2010 ($ Millions)
    • Table 29 U.S. Market For Sickle Cell Anemia Therapeutics By Segment, Through 2010 ($ Millions)
    • Table 30 U.S. Market For Sickle Cell Anemia Diagnostics By Segment, Through 2010 ($ Millions)
    • Table 31 U.S. Market For Pharmaceuticals In The Treatment Of Sickle Cell Anemia By Product Type, Through 2010 ($ Millions)
    • Table 32 U.S. Market For Transfusions In The Treatment Of Anemias By Product Type, Through 2010 ($ Millions)
    • Table 33 U.S. Market For Thalassemia Therapeutics By Segment, Through 2010 ($ Millions)
    • Table 34 U.S. Market For Thalassemia Diagnostics By Segment, Through 2010 ($ Millions)
    • Table 35 U.S. Market For Transfusions In The Treatment Of Thalassemias By Product Type, Through 2010 ($ Millions)
    • Table 36 Mucopolysaccharide Diseases
    • Table 37 U.S. Market For Diagnostics Of Genetic Disease By Disease Type, Through 2010 ($ Millions)
    • Table 38 U.S. Market For Pharmaceutical Treatments Of Genetic Disease By Disease Type, Through 2010 ($ Millions)
    • Table 39 U.S. Market For Transplantation Treatment Of Genetic Disease By Disease Type, Through 2010 ($ Millions)
    • Table 40 U.S. Market For Transfusion Treatment Of Genetic Disease, By Disease Type ($ Millions)
    • Table 41 Monogenic Disease Treatments, Patents By Disease, February 2004-February 2006
    • Table 42 Monogenic Disease Treatments, Patents By Assignee, February 2004-February 2006
    • Table 43 Monogenic Disease Treatments, Patents By Region February 2004-February 2006
    • Table 44 Monogenic Disease Treatments, Patents By Institution Type, February 2004-February 2006
  • List Of Figures
    • Summary Figure: U.S. Market For Therapeutics And Diagnostics For Genetic Diseases, By Segment, 2000-2010 ($ Millions)
    • Figure 1 U.S. Market For Cystic Fibrosis Therapeutics By Segment, 2000-2010 ($ Millions)
    • Figure 2 U.S. Market For Cystic Fibrosis Diagnostics Testing By Segment, 2000-2010 ($ Millions)
    • Figure 3 U.S. Market For Muscular Dystrophy Therapeutics, By Segment, 2000-2010 ($ Millions)
    • Figure 4 U.S. Market For Dmd/Bmd Diagnostics By Segment, 2000-2010 ($ Millions)
    • Figure 5 U.S. Market For Hemophilia Therapeutics By Segment, 2000- 2010 ($ Millions)
    • Figure 6 U.S. Market For Hemophilia Diagnostics By Segment, 2000-2010 ($ Millions)
    • Figure 7 U.S. Market For Hereditary Hemachromatosis Therapeutics, By Segment, 2000-2010 ($ Millions)
    • Figure 8 U.S. Market For Hereditary Hemachromatosis By Confirmatory Diagnosis, 2002-2010 ($ Millions)
    • Figure 9 U.S. Market For Polycystic Kidney Disease Therapeutics By Segment, 2000-2010 ($ Millions)
    • Figure 10 U.S. Market For Polycystic Kidney Disease Diagnostics By Segment, 2000-2010 ($ Millions)
    • Figure 11 U.S. Market For Sickle Cell Anemia Therapeutics By Segment, 2000-2010 ($ Millions)
    • Figure 12 Market For Sickle Cell Anemia Diagnostics By Segment, Through 2010 ($ Millions)
    • Figure 13 U.S. Market For Thalassemia Therapeutics By Segment, 2000-2010 ($ Millions)
    • Figure 14 U.S. Market For Thalassemia Diagnostics By Segment, 2000-2010 ($ Millions)
    • Figure 15 U.S. Market For Diagnostics Of Genetic Disease By Disease Type, 2000-2010 ($ Millions)